Narong Asayut1, Phayom Sookaneknun2, Surasak Chaiyasong3, Kritsanee Saramunee3. 1. Doctor of Philosophy in Pharmacy Program, Mahasarakham University, Kantharawichai, Thailand. 2. Primary Care Practice Research Unit, Kantharawichai, Thailand. 3. Social Pharmacy Research Unit, Faculty of Pharmacy, Mahasarakham University, Kantarawichai, Thailand.
Abstract
OBJECTIVES: Identify costs, outcomes and stakeholders' perspectives associated with incorporation of community pharmacy services into the Thai National Health Insurance System and their values to all stakeholders. METHODS: Using a combination of search terms, a comprehensive literature search was performed using the Thai Journal Citation Index Centre, Health System Research Institute database, PubMed and references from recent reviews. Identified studies were published between January 2000 and December 2014. The review included publications in English and Thai on primary research undertaken in community pharmacies associated with the National Health Insurance System. Two independent authors performed study selection, data extraction and quality assessment. KEY FINDINGS: The literature search yielded 251 titles, with 18 satisfying the inclusion criteria. Clinical outcomes of community pharmacy services included control and reduction in blood pressure and blood sugar, improved adherence to medications, an increase in acceptance of interventions, and an increase in healthy behaviours. Thirty-three percentage of those at risk of diabetes and hypertension achieved normal blood sugar and blood pressure levels after being followed for 2-6 months by a community pharmacist. The cost of collaborative screening by community pharmacies and primary care units was US$ 4.5. Diabetes management costs were US$ 5.1-30.7. Community pharmacists reported high satisfaction rates. Stakeholders' perspectives revealed support for the community pharmacists' roles and the inclusion of community pharmacies as partners with the National Health Insurance System. CONCLUSIONS: Community pharmacy services improved outcomes for diabetic and hypertensive patients. This review supports the feasibility of incorporating community pharmacies into the Thai National Health System.
OBJECTIVES: Identify costs, outcomes and stakeholders' perspectives associated with incorporation of community pharmacy services into the Thai National Health Insurance System and their values to all stakeholders. METHODS: Using a combination of search terms, a comprehensive literature search was performed using the Thai Journal Citation Index Centre, Health System Research Institute database, PubMed and references from recent reviews. Identified studies were published between January 2000 and December 2014. The review included publications in English and Thai on primary research undertaken in community pharmacies associated with the National Health Insurance System. Two independent authors performed study selection, data extraction and quality assessment. KEY FINDINGS: The literature search yielded 251 titles, with 18 satisfying the inclusion criteria. Clinical outcomes of community pharmacy services included control and reduction in blood pressure and blood sugar, improved adherence to medications, an increase in acceptance of interventions, and an increase in healthy behaviours. Thirty-three percentage of those at risk of diabetes and hypertension achieved normal blood sugar and blood pressure levels after being followed for 2-6 months by a community pharmacist. The cost of collaborative screening by community pharmacies and primary care units was US$ 4.5. Diabetes management costs were US$ 5.1-30.7. Community pharmacists reported high satisfaction rates. Stakeholders' perspectives revealed support for the community pharmacists' roles and the inclusion of community pharmacies as partners with the National Health Insurance System. CONCLUSIONS: Community pharmacy services improved outcomes for diabetic and hypertensivepatients. This review supports the feasibility of incorporating community pharmacies into the Thai National Health System.
Authors: Pooja Lagisetty; Alex Smith; Derek Antoku; Suzanne Winter; Michael Smith; Mary Jannausch; Hae Mi Choe; Amy S B Bohnert; Michele Heisler Journal: Am J Health Syst Pharm Date: 2020-05-07 Impact factor: 2.637
Authors: Peter E H Schwarz; Patrick Timpel; Lorenz Harst; Colin J Greaves; Mohammed K Ali; Jeffrey Lambert; Mary Beth Weber; Mohamad M Almedawar; Henning Morawietz Journal: J Am Coll Cardiol Date: 2018-10-09 Impact factor: 24.094